Research Topics
| John SampsonSummaryAffiliation: Duke University Medical Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastomaJohn H Sampson
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America
PLoS ONE 7:e31046. 2012..However, therapeutic approaches are complicated by the inadvertent inhibition of IL-2Rα expressing anti-tumor effector T-cells...
Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodiesJohn H Sampson
Department of Surgery Neurosurgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Neurosurg Focus 20:E14. 2006..The purpose of this study was to determine if CED would provide a larger volume of distribution (Vd) of a radiolabeled monoclonal antibody (mAb) than a bolus injection...- Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant gliomaJohn H Sampson
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
Semin Immunol 20:267-75. 2008..The recurrence of EGFRvIII-negative tumors in our patients, however, highlights the need for targeting a broader repertoire of tumor-specific antigens... - Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case studyJohn H Sampson
Duke University Medical Center, Durham, NC 27710, USA
Neuro Oncol 7:90-6. 2005..This report describes a dramatic and sustained clinical and radiographic response in a patient with a bifrontal glioblastoma multiforme treated with intratumoral infusion of a novel targeted toxin, TP-38... - Microvascular decompression for glossopharyngeal neuralgia: long-term effectiveness and complication avoidanceJohn H Sampson
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Box 3807, Durham, NC 27710, USA
Neurosurgery 54:884-9; discussion 889-90. 2004.... - Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumorsJohn H Sampson
Division of Neurosurgery, Department of Surgery, Box 3050, Room 220 Sands Building, Duke University Medical Center, Durham, NC 27710, USA
Neuro Oncol 10:320-9. 2008..However, the potential efficacy of drugs delivered by this technique may be severely constrained by ineffective infusion in many patients... 
Poor drug distribution as a possible explanation for the results of the PRECISE trialJohn H Sampson
Division of Neurosurgery, Department of Surgery, Duke University, Durham, North Carolina, USA
J Neurosurg 113:301-9. 2010..The purpose of the present work was to retrospectively analyze the expected drug distribution based on catheter positioning data available from the CED arm of the PRECISE trial...- Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioningJohn H Sampson
Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Neurosurgery 60:ONS89-98; discussion ONS98-9. 2007..The primary objective of this study was to quantitatively describe the distribution of a high molecular weight agent by CED relative to target anatomy and catheter position in patients with malignant gliomas... - Unarmed, tumor-specific monoclonal antibody effectively treats brain tumorsJ H Sampson
Department of Surgery Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
Proc Natl Acad Sci U S A 97:7503-8. 2000..These data indicate that an unarmed, tumor-specific mAb may be an effective immunotherapy against human tumors and potentially other pathologic processes in the "immunologically privileged" central nervous system... - Is cytomegalovirus a therapeutic target in glioblastoma?John H Sampson
Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 17:4619-21. 2011..Is the level of CMV infection within tumor cells sufficient to drive important oncogenic or immunosuppressive processes? Can CMV serve as a target for therapeutic intervention?.. - Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humansJohn H Sampson
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Neurosurgery 69:668-76. 2011..CED is currently limited by suboptimal methodologies for monitoring the delivery of therapeutic agents that would permit technical optimization and enhanced therapeutic efficacy... - Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusionsJohn H Sampson
Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
Neuro Oncol 9:343-53. 2007..6% of catheters. Routine use of this algorithm, and its further developments, should improve prospective selection of catheter trajectories, and thereby improve the efficacy of drugs delivered by this promising technique... - Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiformeJames J Vredenburgh
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
Int J Radiat Oncol Biol Phys 82:58-66. 2012..To determine the safety of the addition of bevacizumab to standard radiation therapy and daily temozolomide for newly diagnosed glioblastoma multiforme (GBM)... - Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomasAnnick Desjardins
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 14:7068-73. 2008..We did a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan for patients with recurrent grade 3 malignant glioma... - Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapyDavid A Reardon
Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
J Neurooncol 103:371-9. 2011..Alternative treatment strategies remain critically needed for this indication... - Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant gliomaJennifer A Quinn
Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
Cancer 115:2964-70. 2009..The trial was designed to determine the maximum tolerated dose (MTD) and toxicity of irinotecan (CPT-11) when administered with temozolomide (TMZ) and O(6)-benzylguanine (O(6)-BG)... - Clinical applications of a peptide-based vaccine for glioblastomaCharles W Kanaly
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Box 3050, 220 Sands Building, Research Drive, Durham, NC 27710, USA
Neurosurg Clin N Am 21:95-109. 2010.... - Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapyJennifer A Quinn
Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
J Neurooncol 95:393-400. 2009..The lack of correlation of activity with MGMT expression is intriguing, but needs further evaluation in subsequent trials... - Clinical immunotherapy for brain tumorsPeter E Fecci
Departments of Neurosurgery and Pathology, Duke University Medical Center, Durham, NC 27710, USA
Neuroimaging Clin N Am 12:641-64. 2002..Preclinical studies continue to play an important role in refining this form of active immunotherapy... - Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastomaJohn H Sampson
Duke University Medical Center, Durham, NC 27710, USA
J Clin Oncol 28:4722-9. 2010..Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal tissues but widely expressed in glioblastoma multiforme (GBM) and other neoplasms... - Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxinJohn H Sampson
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
AJR Am J Roentgenol 188:703-9. 2007..Our purpose was to test the hypothesis that hyperintense signal changes on T2-weighted images produced by such infusions can be used to track drug distribution... - Bevacizumab plus irinotecan in recurrent glioblastoma multiformeJames J Vredenburgh
Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
J Clin Oncol 25:4722-9. 2007..We performed a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan... - Immunotherapy of surgical malignanciesMichael A Morse
Duke University Medical Center, Durham, North Carolina, USA
Curr Probl Surg 41:15-132. 2004 - Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant gliomaJennifer A Quinn
Departments of Surgery, Duke University Medical Center, PO Box 3624, Durham, NC 27710, USA
J Clin Oncol 27:1262-7. 2009.... - Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cellsPeter E Fecci
Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 12:4294-305. 2006..This leads to safe enhancement of tumor immunity in a murine glioma model that recapitulates the tumor-induced changes to the CD4 and T(reg) compartments seen in patients with malignant glioma... - Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteersChris A Learn
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 12:7306-15. 2006.... - EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cellsHidenobu Ochiai
Department of Surgery Neurosurgery, Duke University Medical Center, Box 3050, Durham, NC, 27710, USA
Cancer Immunol Immunother 57:115-21. 2008..However, delayed and often dramatic antitumor responses seen in human studies with targeted toxins led us to hypothesize that immunologic responses may be a secondary mechanism that enhances the therapeutic efficacy of these novel drugs... - Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa)Amy B Heimberger
Department of Surgery, Neurosurgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 8:3496-502. 2002..On the basis of these observations, we believe that clinical trials of ZD1839 against brain tumors expressing EGFR are warranted, but that special consideration should be given to tumors that coexpress EGFRvIII... - Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiformeChris A Learn
Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 10:3216-24. 2004..However, this decrease does not effectively inhibit the biologically relevant processes of DNA synthesis, cellular growth, and invasion in cells expressing EGFRvIII... - Adoptive immunotherapy for malignant gliomaDuane A Mitchell
Department of Pathology and Department of Surgery, Duke University Medical Center, Box 3807, Durham, NC 27710, USA
Cancer J 9:157-66. 2003.... - Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccinesLee A Selznick
Division of Neurosurgery, Duke University Medical Center, Durham, NC, USA
Neurosurg Rev 31:141-55; discussion 155. 2008..This review will discuss the scientific background, therapeutic potential, and clinical limitations of these novel strategies with a focus on those that have made it to clinical trials... - Cryptococcal meningitis in patients with glioma: a report of two casesJonathan D Choi
Division of Neurosurgery, Department of Surgery, Duke University School of Medicine, Durham, NC 27705, USA
J Neurooncol 89:51-3. 2008..This report of two cases highlights the importance of examining the efficacy of prophylactic antibiotic and/or antifungal regimens in this patient population due to their increased risk of opportunistic infections... - Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastomaDavid A Reardon
Department of Surgery, Duke University Medical Center, Durham, NC, 27710, USA
J Neurooncol 101:57-66. 2011..In conclusion, sorafenib can be safely administered with daily temozolomide, but this regimen has limited activity for recurrent GBM. Co-administration of EIAEDs can lower sorafenib exposures in this population... - Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant gliomaJennifer A Quinn
Dept of Medicine, Division of Neurology, Duke University Medical Center, Durham, NC, USA
Neuro Oncol 11:556-61. 2009..This study provides the foundation for a phase II trial of O(6)-BG in combination with a 5-day dosing schedule of TMZ in TMZ-resistant MG... - Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastomaDuane A Mitchell
Duke University Medical Center, Division of Neurosurgery, Department of Surgery, Durham, NC 27710, USA
Neuro Oncol 10:10-8. 2008.... - Clinical trial end points for high-grade glioma: the evolving landscapeDavid A Reardon
The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
Neuro Oncol 13:353-61. 2011..Technical advances in imaging as well as improved survival for patients with HGG support the further development of auxiliary end points evaluating novel imaging approaches as well as measures of patient function and well being... - Immunotherapy approaches for malignant glioma from 2007 to 2009Laura A Johnson
Duke Brain Tumor Immunotherapy Program, Preston Robert Tisch Brain Tumor Center, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, DUMC 3050, Sands Research Building, Durham, NC 27710, USA
Curr Neurol Neurosci Rep 10:259-66. 2010..We compare and discuss the current state of the art of clinical immunotherapy treatment, as well as its limited successes, pitfalls, and future potential... - Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1Dale Ding
School of Medicine, Duke University Medical Center, DUMC, Box 3050, 220 Sands Building, Research Drive, Durham, NC 27710, USA
J Neurooncol 98:1-7. 2010..Our data supports the use of Gd-DTPA, as a surrogate tracer, co-infused with MR1-1 for drug distribution monitoring in patients with GBM... - An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiformeJohn H Sampson
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Mol Cancer Ther 8:2773-9. 2009..7 months (C.I.(95), 14.5-25.6). Overall median survival from time of histologic diagnosis was 22.8 months (C.I.(95), 17.5-29). This study establishes the EGFRvIII mutation as a safe and immunogenic tumor-specific target for immunotherapy... - Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant gliomaRichard G Everson
Division of Neurosurgery, Department of Surgery, Box 3050 Med Ctr, Preston Robert Tisch Brain Tumor Center at Duke University, Durham, NC 27710, USA
Expert Rev Anticancer Ther 8:717-32. 2008.... - EGFRvIII-targeted vaccination therapy of malignant gliomaBryan D Choi
Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Brain Pathol 19:713-23. 2009..Additionally, the corresponding therapeutic outcomes observed in these studies lend credence to the potential role of peptide-based vaccination strategies among emerging antitumor immunotherapies in patients with malignant glioma... - Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastomaDavid A Reardon
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
J Neurooncol 96:219-30. 2010..029). Erlotinib plus sirolimus was well tolerated but had negligible activity among unselected recurrent GBM patients. (ClinicalTrials.gov number: NCT0062243)... - Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccinesRobert J Schmittling
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
J Immunol Methods 339:74-81. 2008..Using this assay, we found that significant levels of antibody for tumor-specific antigen EGFRvIII (>4 microg/mL) and KLH could be induced after vaccination with PEPvIII-KLH... - Toward effective immunotherapy for the treatment of malignant brain tumorsDuane A Mitchell
Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA
Neurotherapeutics 6:527-38. 2009.... - Proteomic and immunologic analyses of brain tumor exosomesMichael W Graner
Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
FASEB J 23:1541-57. 2009..They can escape the blood-brain barrier, with potential systemic and distal signaling and immune consequences... - Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiformeJennifer A Quinn
Department of Surgery, Pathology, Biostatistics, and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 15:1064-8. 2009.... - Selective modification of antigen-specific T cells by RNA electroporationDuane A Mitchell
Division of Neurosurgery, Department of Surgery, Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC 27710, USA
Hum Gene Ther 19:511-21. 2008.... - Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant gliomaJennifer A Quinn
Department of Surgery, Duke University Medical Center, Durham, NC, USA
J Clin Oncol 23:7178-87. 2005..In addition, plasma concentrations of O6-BG and O6-benzyl-8-oxoguanine were evaluated after O6-BG... - Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial resultsDavid A Reardon
Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA
J Nucl Med 47:912-8. 2006.... - Immunotherapy of malignant brain tumorsDuane A Mitchell
Division of Neurosurgery, Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke, NC 27710, USA
Immunol Rev 222:70-100. 2008.... - Phase II trial of gefitinib in recurrent glioblastomaJeremy N Rich
Duke University Medical Center, Box 2900, Durham, NC 27710, USA
J Clin Oncol 22:133-42. 2004..To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma... - Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant bJohn H Sampson
Division of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
J Neurooncol 65:27-35. 2003..9 weeks. Overall, 3 of 15 patients, with residual disease at the time of therapy, have demonstrated radiographic responses and one patient with a complete response and has survived greater than 83 weeks... - Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancerPeter M Grossi
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 9:5514-20. 2003..001). CONCLUSION: ICM of trastuzumab is safe and superior to systemic delivery as therapy for HER2-overexpressing intracerebral neoplasms in an athymic rat model... - Phase 2 trial of BCNU plus irinotecan in adults with malignant gliomaDavid A Reardon
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
Neuro Oncol 6:134-44. 2004..9 weeks for recurrent anaplastic astrocytoma/ anaplastic oligodendroglioma patients. We conclude that the activity of BCNU plus CPT-11 for patients with MG appears comparable to that of CPT-11 alone and may be more toxic... - Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant gliomaDavid A Reardon
AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
Clin Cancer Res 12:860-8. 2006.... - Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiformeDavid A Reardon
Department of Medicine, Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA
J Clin Oncol 23:9359-68. 2005.... - Phase II trial of temozolomide in patients with progressive low-grade gliomaJennifer A Quinn
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
J Clin Oncol 21:646-51. 2003..We have extended these results, and now we report results of a phase II trial of Temodar for patients with progressive, low-grade glioma... - Preoperative functional MR imaging localization of language and motor areas: effect on therapeutic decision making in patients with potentially resectable brain tumorsJeffrey R Petrella
Department of Radiology, Division of Neuroradiology, Brain Imaging and Analysis Center, Duke University Medical Center, Box 3808, Durham, NC 27710 3808, USA
Radiology 240:793-802. 2006..To prospectively evaluate the effect of preoperative functional magnetic resonance (MR) imaging localization of language and motor areas on therapeutic decision making in patients with potentially resectable brain tumors... - Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanomaAmy B Heimberger
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Neurosurgery 50:158-64; discussion 164-6. 2002.... - Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen systemCarol J Wikstrand
Department of Pathology, Box 3156, Medical Center, Duke University Medical Center, Durham, NC 27710, USA
Cancer Immunol Immunother 50:639-52. 2002.... - Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomasDavid A Reardon
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
J Clin Oncol 20:1389-97. 2002..To assess the efficacy and toxicity of intraresection cavity (131)I-labeled murine antitenascin monoclonal antibody 81C6 and determine its true response rate among patients with newly diagnosed malignant glioma... - Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant gliomaJennifer A Quinn
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
Neuro Oncol 6:145-53. 2004.... - Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant gliomaJennifer A Quinn
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
J Clin Oncol 20:2277-83. 2002.... - Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomasAnnick Desjardins
Department of Medicine, Division of Neurology, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
J Neurooncol 83:53-60. 2007..We performed the current phase 2 study to evaluate this regimen among patients with recurrent WHO grade III malignant glioma (MG)... - Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunityChris A Learn
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, United States
J Neuroimmunol 182:63-72. 2007..Our findings support our hypothesis that glioma phenotype in vitro may be quite different in vivo and significantly altered by in situ growth factors and other invading cell populations... - Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasionAnita Lal
Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
Cancer Res 62:3335-9. 2002..Furthermore, inhibitors of EGFR (OSI-774 and Tyrphostin AG1478) selectively down-regulated these molecular effectors in glioblastoma cells, eliminating enhanced invasion... - The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumorsPeter E Fecci
Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
J Neurooncol 64:161-76. 2003..The future success of clinical trials will depend on the optimization and standardizing of procedures for DC generation, loading, and administration... - Surgical management of petroclival meningiomas: defining resection goals based on risk of neurological morbidity and tumor recurrence rates in 137 patientsKenneth M Little
Division of Neurosurgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Neurosurgery 56:546-59; discussion 546-59. 2005..By selectively pursuing an NTR rather than a GTR, neurological morbidity was reduced significantly without significantly increasing the rate of tumor recurrence... - Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell functionPeter E Fecci
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 13:2158-67. 2007..Our murine glioma model recapitulates these findings. Here, we investigate the effects of systemic CTLA-4 blockade in this model... - Bevacizumab fails to treat temporal paraganglioma: discussion and case illustrationHamidreza Aliabadi
Department of Surgery, Division of Neurosurgery, Duke University Medical Center, 220 Sands Building, Research Drive, Box 3050, Durham, NC 27710, USA
J Neurooncol 98:427-30. 2010..This patient was treated with bevacizumab prior to surgical treatment; radiographic imaging at 3 months, however, showed no significant response. We discuss possible reasons for treatment failure... - Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant gliomaPeter E Fecci
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Cancer Res 66:3294-302. 2006..These findings dramatically alter our understanding of depressed cellular immune function in patients with malignant glioma and advance a role for T(regs) in facilitating tumor immune evasion in the central nervous system... - Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecinHidenobu Ochiai
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
Neurol Med Chir (Tokyo) 46:485-9; discussion 489-90. 2006..005). These results suggest that intrathecal treatment with 9NC may be useful for patients with GBM neoplastic meningitis... - Viruses in the treatment of malignant gliomaRichard G Everson
Expert Rev Neurother 7:321-4. 2007 - Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case studyAmy B Heimberger
Department of Neurosurgery, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
Neuro Oncol 10:98-103. 2008..In fact, the temozolomide-induced lymphopenia may prove to be synergistic with a peptide vaccine secondary to inhibition of regulatory T cells or their delayed recovery... - Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety resultsMichael A Vogelbaum
Brain Tumor and Neuro Oncology Center, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Neurosurgery 61:1031-7; discussion 1037-8. 2007.... - Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studiesSandeep Kunwar
Department of Neurosurgery, University of California, San Francisco, California 94143 0350, USA
Neurosurg Focus 20:E15. 2006..Cintredekin besudotox (also known as IL13- PE38QQR) is a recombinant chimeric cytotoxin consisting of interleukin-13 and a truncated exotoxin produced by the Pseudomonas aeruginosa bacterium, which targets malignant glioma cells... - Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumorsAmy B Heimberger
Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Unit 442, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Clin Cancer Res 9:4247-54. 2003..In the study described here, we tested in mouse models a vaccine consisting of a peptide encompassing the tumor-specific mutated segment of EGFRvIII (PEP-3) conjugated to keyhole limpet hemocyanin [KLH (PEP-3-KLH)]... - Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study GroupSandeep Kunwar
Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143 0350, USA
J Clin Oncol 25:837-44. 2007..We assessed the use of intracerebral CED to deliver CB in patients with recurrent malignant glioma (MG)... - Convection-enhanced delivery of therapeutics for brain disease, and its optimizationRaghu Raghavan
Therataxis, LLC, Baltimore, Maryland 21210 2415, USA
Neurosurg Focus 20:E12. 2006..In the present paper we review key features of CED as well as modeling of the procedure and indulge in informed speculation on optimizing the direct delivery of therapeutic agents into brain tissue... - Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirusHidenobu Ochiai
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 12:1349-54. 2006..CONCLUSION: These results suggest that intrathecal treatment with PVS-RIPO may be useful for treatment of neoplastic meningitis in patients with glioblastoma multiforme and provides a rationale for clinical trials in this area... - Viruses in the treatment of brain tumorsPeter E Fecci
Departments of Neurosurgery and Pathology, Duke University Medical Center, Durham, NC 27710, USA
Neuroimaging Clin N Am 12:553-70. 2002..Despite some promise afforded by these trials, further studies are warranted; the investigation of additional viruses to play these roles is inevitable and is now precedented... - Combating immunosuppression in gliomaEleanor A Vega
Duke University School of Medicine, Department of Surgery, Division of Neurosurgery, 221 Sands Building, Durham, NC 27710, USA
Future Oncol 4:433-42. 2008..In addition, vaccination against Foxp3 has been explored. The results of these studies have been encouraging; combating immunosuppression may be one key to improving prognosis in malignant glioma... - A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cellsLing Yuan Kong
Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 14:5759-68. 2008..We hypothesized that WP1066, a novel STAT3 blockade agent, has marked antitumor activity, even against the melanoma metastasis to brain, a site typically refractory to therapies... - Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirusHidenobu Ochiai
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 10:4831-8. 2004..CONCLUSIONS: Our findings suggest oncolytic PV recombinants as a viable treatment option for CNS complications of breast cancer... - Poliovirus receptor CD155-targeted oncolysis of gliomaMelinda K Merrill
Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA
Neuro Oncol 6:208-17. 2004..Upregulation of the molecular target CD155 rendered explant cultures of all studied tumors highly susceptible to a prototype oncolytic poliovirus recombinant. Our observations support the clinical application of such agents against HGL...
Research Grants
- Intracerebral Infusion of Radiolabeled Specific AntibodyJohn Sampson; Fiscal Year: 2006..abstract_text> ..
- Dendritic Cell Immunotherapy of Malignant GliomasJohn Sampson; Fiscal Year: 2006..abstract_text> ..
- RNA-based Immunotherapy Targeting Antigens Unique to Brain Tumor Stem CellsJohn Sampson; Fiscal Year: 2009..PHS 398/2590 (Rev. 11/07) Page 1 Continuation Format Page ..
- MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AWJohn Sampson; Fiscal Year: 2004....
- RNA-based Immunotherapy Targeting Antigens Unique to Brain Tumor Stem CellsJohn H Sampson; Fiscal Year: 2010..In this proposal we will see if targeting antigens preferentially or uniquely expressed by BTSCs will enhance the efficacy and reduce toxicity of immunotherapy. ..